SELB - セレクタ・バイオサイエンシズ （Selecta Biosciences Inc.） セレクタ・バイオサイエンシズSELBのチャート
SELBの企業情報
| symbol | SELB |
|---|---|
| 会社名 | Selecta Biosciences Inc （セレクタ・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 セレクタ・バイオサイエンス(Selecta Biosciences Inc.)は臨床段階のバイオ医薬品会社である。同社は合成ワクチン粒子（SVP）技術を使用して、希少疾患および重症疾患を治療するために免疫系を調節するように設計された標的療法を発見・開発する。同社はヒト疾患の治療および予防のためのナノ粒子免疫調節薬の研究・開発に従事する。同社の製品候補は、臨床および前臨床開発の各段階にある。そのSVP技術は、生物分解性ナノ粒子に免疫調節物質を封入し、抗原特異的な免疫寛容を誘導し、生命維持生物製剤に応答する抗薬物抗体（ADA）の形成を軽減する。主要製品候補であるSEL-212は、痛風の生物学的治療薬として設計された治療用酵素とそのSVP技術の組み合わせである。 セレクタ・バイオサイエンシズは米国のバイオ医薬品企業。臨床段階で、合成粒子ワクチン(SVP)技術を利用し難病の免疫療法による治療の開発に従事。同社のSVP技術は、患者の免疫系と合わない場合に、免疫調整物質を生物分解可能なナノ粒子にカプセル化するテクノロジ―。本社はマサチュ―セッツ州ウォ―タ―タウン。 selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat |
| 本社所在地 | 480 Arsenal Way Watertown MA 02472 USA |
| 代表者氏名 | Omid Farokhzad オミッド・ファロクザド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-923-1400 |
| 設立年月日 | 39417 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 64人 |
| url | www.selectabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/selb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -66.76500 |
| 終値（lastsale） | 13.3197 |
| 時価総額（marketcap） | 298310438.7051 |
| 時価総額 | 時価総額（百万ドル） 309.29130 |
| 売上高 | 売上高（百万ドル） 0.04400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 264.27530 |
| 当期純利益 | 当期純利益（百万ドル） -68.90400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Selecta Biosciences Inc revenues decreased from $163K to $0K. Net loss increased 12% to $34.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 15% to $24.4M (expense) Stock-based Compensation in SGA increase of 60% to $1.3M (expense). |
SELBのテクニカル分析
SELBのニュース
Selecta Biosciences (NASDAQ:SELB) Stock Rating Lowered by StockNews.com 2023/05/07 05:52:42 The AM Reporter
Selecta Biosciences (NASDAQ:SELB – Get Rating) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday. Several other research firms have also weighed in on SELB. Mizuho cut their target price on Selecta Biosciences from $5.00 to $4.00 and set a […]
Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript 2023/05/04 23:06:14 Seeking Alpha
Selecta Biosciences, Inc. (NASDAQ:NASDAQ:SELB) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ETCompany ParticipantsBlaine Davis - CFOCarsten Brunn - CEO, President &…
Selecta Biosciences GAAP EPS of -$0.14 misses by $0.05, revenue of $5.9M misses by $6.24M 2023/05/04 11:50:06 Seeking Alpha
Selecta Biosciences press release (SELB): Q1 GAAP EPS of -$0.14 misses by $0.05.Revenue of $5.9M (-82.6% Y/Y) misses by $6.24M.$127.5 million in cash, cash equivalents, restricted…
Selecta Biosciences Q1 2023 Earnings Preview 2023/05/03 17:08:47 Seeking Alpha
Selecta Biosciences (SELB) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open.The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is…
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update 2023/04/28 20:05:00 GlobeNewswire
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update 2023/04/28 20:05:00 GlobeNewswire
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.
Selecta Biosciences PT Raised to $5 at H.C. Wainwright 2023/03/23 10:37:06 Investing.com
https://www.investing.com/news/pro/selecta-biosciences-pt-raised-to-5-at-hc-wainwright-432SI-3037560
Selecta Reports Promising Phase 3 Data in Chronic Refractory Gout 2023/03/21 13:47:13 TipRanks
Shares of biopharmaceutical company Selecta Biosciences (NASDAQ:CELB) are trending today after it announced positive topline results from a Phase 3…
Thinking about buying stock in Selecta Biosciences, On Holding AG, eMagin, Harmonic, or Canadian Solar? 2023/03/21 12:34:00 Benzinga
NEW YORK , March 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SELB, ONON, EMAN, HLIT, and CSIQ. … Full story available on Benzinga.com
Selecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trials 2023/03/21 10:30:19 Seeking Alpha
Selecta Biosciences (SELB) and Swedish Orphan Biovitrum (Sobi) (BIOVF) said SEL-212 met the main goals of two phase 3 trials to treat adult patients with chronic refractory gout.Gout is…
Thinking about buying stock in Applied UV, Nio, Wejo Group, Helius Medical Technologies, or Selecta Biosciences? 2022/06/09 13:31:00 Benzinga
NEW YORK , June 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, NIO, WEJO, HSDT, and SELB. … Full story available on Benzinga.com
Selecta Biosciences Inc. (NASDAQ: SELB) Stock: Can Value Hunters Buy It? 2022/06/01 15:30:00 Stocks Register
The trading price of Selecta Biosciences Inc. (NASDAQ:SELB) closed higher on Tuesday, May 31, closing at $0.88, 14.96% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7801 … Selecta Biosciences Inc. (NASDAQ: SELB) Stock: Can Value Hunters Buy It? Read More »
Let’s Talk About How Selecta Biosciences Inc. (NASDAQ: SELB) Stock Is Doing. 2022/05/31 12:30:00 Marketing Sentinel
In the last trading session, 2.14 million shares of the Selecta Biosciences Inc. (NASDAQ:SELB) were traded, and its beta was 1.36. Most recently the company’s share price was $0.77, and it changed around $0.07 or 9.38% from the last close, which brings the market valuation of the company to $106.55M. SELB currently trades at a … Let’s Talk About How Selecta Biosciences Inc. (NASDAQ: SELB) Stock Is Doing. Read More »
Selecta Biosciences Inc. (NASDAQ: SELB) Stock Forecast For 2022: Increases Growth Prospects To $9 Per Share 2022/05/23 14:30:00 Marketing Sentinel
In the last trading session, 1.89 million Selecta Biosciences Inc. (NASDAQ:SELB) shares changed hands as the company’s beta touched 1.30. With the company’s per share price at $0.80 changed hands at $0.03 or 2.76% during last session, the market valuation stood at $117.57M. SELB’s last price was a discount, traded about -560.0% off its 52-week … Selecta Biosciences Inc. (NASDAQ: SELB) Stock Forecast For 2022: Increases Growth Prospects To $9 Per Share Read More »
7 Cheap Biotech Stocks to Buy Now 2022/05/19 22:00:38 InvestorPlace
This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ): Clinical-stage biotech with truckloads of cash to take its novel immune tolerance platform past the finish line. Bluebird Bio ( BLUE ): Speculative biotech with a colossal growth runway if the FDA gives its gene therapies the green light. Vistagen Therapeutics ( VTGN ): Unique portfolio of therapeutics which target the nervous system in an industry set for tremendous growth ahead. BioNano Genomics Inc ( BNGO ): This meme stock could develop a long-term recurring revenue-generating machine with its genome image editing tool. Verastem ( VSTM ): This startup develops novel cancer treatments with the goal of delivering the best-in-class RAS pathway product. BioCryst Pharmaceuticals ( BCRX ): Biotech with a robust rare disease drug portfolio and strong liquidity. Source: Mongkolchon Akesin / Shutterstock.com Amidst immense market volatility, investors favor value-oriented sectors to minimize risk.